Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Winlevi (clascoterone) in skin of color patients with acne
NCT06415305Phase 4Completed
- Sponsor
- Sun Pharma
- Start
- Sep 2023
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clascoterone in acne vulgaris, sponsored by Sun Pharma. Primary endpoint: Investigator's Global Assessment Clear or Almost Clear at 16 weeks. Started Sep 2023; status: completed.
02
Drugs
clascoterone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06415305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415305.